Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.

Trial Details

NCT ID
NCT06175000
Phase
PHASE2
Sponsor
Providence Health & Services
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Cognitive Assessment
  • Obinutuzumab
  • Quality of Life Assessment
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Portland, Oregon, United States|45.52345,-122.67621
  • Hershey, Pennsylvania, United States|40.28592,-76.65025
  • Burlington, Vermont, United States|44.47588,-73.21207

Key Eligibility Criteria

  • CD20+ B-cell primary central nervous system lymphoma (PCNSL) confirmed at the time of diagnosis by histology, cytology, or immunocytochemistry from…
  • Must have undergone first-line treatment with a high-dose methotrexate-based chemotherapy regimen with or without brain radiotherapy; high-dose met…
  • Must be within 75 days of completion of first-line treatment regimen at the time of randomization; must have achieved objective response (PR or CR/…
  • Brain magnetic resonance imaging (MRI) documenting objective response must be obtained within 30 days before randomization

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →